Activatable cytokine polypeptides and methods of use thereof
AssigneeWerewolf Therapeutics, Inc.
InventorsWilliam WINSTON, Daniel HICKLIN, Jose Andres SALEMERON-GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
Life of this patent
Estimating the term…
Loading patent…
AssigneeWerewolf Therapeutics, Inc.
InventorsWilliam WINSTON, Daniel HICKLIN, Jose Andres SALEMERON-GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
Estimating the term…
The disclosure features fusion proteins that are conditionally active variants of a cytokine of interest. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g. a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling. Typically, the fusion proteins further comprise an in vivo half-life extension element, which may be cleaved from the cytokine in the tumor microenvironment.
1-68. (canceled)
A method of treating a cancer in a human subject comprising administering to the subject in need thereof an effective amount of therapeutic combination comprising a) an inducible cytokine polypeptide and b) a cellular therapy.
The method of 70, wherein the T-cell therapy comprises activated T cells.
A therapeutic combination comprising a) an inducible cytokine polypeptide and b) a cellular therapy, in an amount effective to treat cancer in a human subject.
A therapeutic combination comprising a) an inducible cytokine polypeptide, b) a cellular therapy, and c) an immune-oncology agent, in an amount effective to treat cancer in a human subject.
Dependencies are inferred from the claim text.